Gastrointestinal
14. Apr 2020
The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease
Background: In Crohn's disease (CD), 10% to 40% of patients do not respond to anti-tumor necrosis factor-α (TNFα) treatment. Currently, there are no biomarkers with adequate sensitivity to separate responders from nonresponders at an early stage.
Aim: The aim of this study was to investigated whe…
Read the publication
Journal:
Authors:
- Mortensen JH,
- Van Haaften WT,
- Karsdal MA,
- Bay-Jensen AC,
- Olinga P,
- Grønbæk H,
- Hvas CL,
- Manon-Jensen T,
- Dijkstra G,
- Dige A,